BioCanRx Funded Core Facilities

BioCanRx has awarded funding to four Canadian academic facilities that offer translational services, including one organization that can support commercialization efforts. The Core Facilities program provides a baseline level of support for core facilities to enable their timely and cost-effective use by researchers of BioCanRx-funded projects.

The funded facilities are:

- **Immunotherapy Monoclonal Antibody Platform**, Montreal Clinical Research Institute (IRCM)
- **Molecular and Cellular Immunology Core (MCIC)**, BC Cancer
- **Biotherapeutics Manufacturing Centre – Virus Manufacturing Facility**, Ottawa Hospital Research Institute
- **IRICoR**, Commercialization Support, Université de Montréal

The purpose of this document is to provide greater detail on the funded core facilities. We are happy to support further engagement with Core Facilities for potential collaboration. Please contact Megan Mahoney, Director of Scientific Affairs (memahoney@biocanrx.com)

Biotherapeutics Manufacturing Centre (BMC)

The Ottawa Hospital

Contract development and manufacturing organization (CDMO) providing turn-key operations, translational facilities, and expertise for viral and cell products.

What is the BMC?

The Biotherapeutics Manufacturing Centre (BMC) is a world-class facility specializing in the development and manufacturing of biotherapeutic products. With over 17 years of experience and support from BioCanRx, BMC has become a trusted partner for early-phase clinical trials across North America, Europe, and Asia.

What do they do?

BMC provides end-to-end support for biotherapeutics manufacturing, including:

- Upstream and downstream process development and optimization
- GMP compliant production of cell and virus products for early phase clinical testing
- GMP compliant product release and stability testing
- Supported by a robust quality management system compliant with ICH Q10, GUI-0001, GUI-0119 (Health Canada), and FDA guidelines (21CFR210, 21CFR211)
- Training for the next generation of biomanufacturing professionals through CanPRIME, Canada's first, work-integrated learning biotherapeutics manufacturing program in Canada

BioCanRx
Canada's Immunotherapy Network
Le réseau canadien d'immunothérapie

BMC

Capabilities

- Six dedicated manufacturing suites
- Over 40 highly skilled staff
- Expertise in over 10 different types of cells and viruses
- Proven track record with products used in clinical trials worldwide
- Support for academic and commercial partners

Notable Products

- Viral immunotherapies for cancer (oncolytic viruses)
- Mesenchymal stem/stromal cells
- CAR-T therapy (cells and lentivirus)
- Genetically engineered endothelial progenitors
- Adeno-Associated Viruses for gene therapy
- Extracellular vesicles
- COVID-19 vaccines

Why BMC?

- Extensive experience with biotherapeutic products
- Robust quality management and compliance
- Comprehensive training and development through CanPRIME
- Proven success in supporting both academic and industry clients

Contact Us:

contactbmc@ohri.ca

ohri.ca/bmc